{"slideshow_credits": null, "snippet": "Sales of Harvoni and an earlier hepatitis C drug, Sovaldi, far exceeded Wall Street expectations and made the company one of the top earners in pharmaceuticals.", "abstract": "Gilead Sciences reports surging first quarter profits, with earnings per share more than doubling to $2.76 from year-earlier period; reports that sales of its hepatitis C drugs reached $4.55 billion, largely reflecting popularity of its new drug, Harvoni.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK"}, "web_url": "http://www.nytimes.com/2015/05/01/business/gilead-hepatitis-drugs-brought-in-4-55-billion-in-first-quarter.html", "lead_paragraph": "Sales of Harvoni and an earlier hepatitis C drug, Sovaldi, far exceeded Wall Street expectations and made the company one of the top earners in pharmaceuticals.", "headline": {"main": "Gilead Hepatitis Drugs Brought In $4.55 Billion in First Quarter", "print_headline": "Gilead Earnings Surge as Sales of Hepatitis Drugs Double, Exceeding Forecasts"}, "_id": "554299de38f0d83d46e51e49", "word_count": "515", "multimedia": [], "pub_date": "2015-05-01T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Gilead Sciences Inc", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Hepatitis", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Harvoni (Drug)", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Company Reports", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "6"}, {"name": "subject", "value": "Sovaldi (Drug)", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": null, "type_of_material": "News"}